May 26, 2021
Via: FierceBiotechThe FDA has crushed Travere Therapeutics’ hopes of seeking accelerated approval in a rare kidney disorder on the strength of existing interim data from a phase 3 clinical trial. Travere said it may have enough data to meet the FDA’s […]
August 26, 2020
Via: FierceBiotechThe FDA’s accelerated approvals program is on shaky ground after a series of surprise rejections, poor communication and COVID-19-focused staff. This is according to analysis by an anonymous FDA consultant out of regulatory firm Prevision Policy, speaking to analysts at […]
September 21, 2023
September 19, 2023
September 14, 2023
September 7, 2023
September 5, 2023
September 1, 2023
August 30, 2023
September 19, 2023